Quantinno Capital Management LP Purchases 39,222 Shares of Bioventus Inc. $BVS

Quantinno Capital Management LP boosted its position in shares of Bioventus Inc. (NASDAQ:BVS) by 119.6% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 72,023 shares of the company’s stock after buying an additional 39,222 shares during the period. Quantinno Capital Management LP owned approximately 0.09% of Bioventus worth $658,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Marshall Wace LLP boosted its position in shares of Bioventus by 0.4% during the 4th quarter. Marshall Wace LLP now owns 288,900 shares of the company’s stock worth $2,149,000 after acquiring an additional 1,281 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Bioventus by 7.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company’s stock worth $211,000 after purchasing an additional 1,538 shares during the last quarter. Mercer Global Advisors Inc. ADV lifted its stake in Bioventus by 16.2% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 13,529 shares of the company’s stock worth $101,000 after purchasing an additional 1,887 shares during the last quarter. Deutsche Bank AG boosted its holdings in shares of Bioventus by 8.2% in the 4th quarter. Deutsche Bank AG now owns 25,138 shares of the company’s stock valued at $187,000 after purchasing an additional 1,908 shares in the last quarter. Finally, Engineers Gate Manager LP boosted its holdings in shares of Bioventus by 6.0% in the 4th quarter. Engineers Gate Manager LP now owns 68,889 shares of the company’s stock valued at $513,000 after purchasing an additional 3,909 shares in the last quarter. 62.94% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on BVS shares. Canaccord Genuity Group upped their price objective on Bioventus from $15.00 to $19.00 and gave the stock a “buy” rating in a research report on Monday. Craig Hallum reiterated a “buy” rating and issued a $18.00 target price on shares of Bioventus in a research report on Thursday, August 6th. Barrington Research set a $18.00 target price on Bioventus in a research note on Thursday, August 6th. Cantor Fitzgerald reissued an “overweight” rating and set a $15.00 target price on shares of Bioventus in a research note on Monday. Finally, Weiss Ratings raised shares of Bioventus from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, August 6th. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, Bioventus presently has an average rating of “Moderate Buy” and a consensus target price of $16.80.

Bioventus Stock Up 2.7%

Shares of BVS opened at $14.68 on Thursday. The stock’s 50-day moving average price is $11.67 and its two-hundred day moving average price is $10.05. Bioventus Inc. has a 12 month low of $6.26 and a 12 month high of $15.89. The company has a market capitalization of $1.23 billion, a PE ratio of 19.07, a PEG ratio of 1.82 and a beta of 0.63. The company has a current ratio of 1.69, a quick ratio of 1.17 and a debt-to-equity ratio of 0.83.

Bioventus (NASDAQ:BVS) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.22 earnings per share for the quarter, hitting the consensus estimate of $0.22. The company had revenue of $153.21 million during the quarter. Bioventus had a net margin of 9.36% and a return on equity of 28.08%. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. On average, analysts anticipate that Bioventus Inc. will post 0.79 EPS for the current year.

Bioventus Profile

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.